Cargando…
Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents
PURPOSE: Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid-related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with other intranasal steroids (INS). METHODS: After a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819470/ https://www.ncbi.nlm.nih.gov/pubmed/27747804 http://dx.doi.org/10.1007/s40801-015-0057-y |
_version_ | 1782425203802898432 |
---|---|
author | Davis, Kourtney J. Hinds, David Motsko, Stephen P. Goehring, Earl Jones, Judith K. |
author_facet | Davis, Kourtney J. Hinds, David Motsko, Stephen P. Goehring, Earl Jones, Judith K. |
author_sort | Davis, Kourtney J. |
collection | PubMed |
description | PURPOSE: Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid-related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with other intranasal steroids (INS). METHODS: After a feasibility study using an electronic medical record database in the UK (1990–2002), a retrospective cohort study was conducted using a large administrative claims database in the USA from 1994 to 2002 comparing the incidence and rate ratios of steroid-related events among intermittent, sub-chronic, and chronic FPNS use and other INS use episodes. RESULTS: Most patients used INS intermittently; power was low to evaluate risk associated with chronic use. Significantly elevated adjusted rate ratios were observed in the US study comparing FPNS with other INS for hypercorticism, sinusitis, abscess, and empyema, as well as a significantly decreased rate ratio for cataracts. The US claims database provided greater granularity on covariates and markers of severity to improve control of confounding for this study and time period, but neither database was able to assess the indication for prescription and the UK study could not address the use of INS without a prescription. CONCLUSIONS: The FPNS results were consistent with the risk profile for INS and did not raise any new safety signals at the time of study conduct, which is consistent with the current safety profile. We were not able to discern the extent of potential off-label use of FPNS or other INS. Differences in the available data and healthcare systems highlight important considerations for database selection in the feasibility phase to assess the precision and limitations prior to formal risk evaluation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40801-015-0057-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4819470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-48194702016-04-10 Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents Davis, Kourtney J. Hinds, David Motsko, Stephen P. Goehring, Earl Jones, Judith K. Drugs Real World Outcomes Original Research Article PURPOSE: Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid-related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with other intranasal steroids (INS). METHODS: After a feasibility study using an electronic medical record database in the UK (1990–2002), a retrospective cohort study was conducted using a large administrative claims database in the USA from 1994 to 2002 comparing the incidence and rate ratios of steroid-related events among intermittent, sub-chronic, and chronic FPNS use and other INS use episodes. RESULTS: Most patients used INS intermittently; power was low to evaluate risk associated with chronic use. Significantly elevated adjusted rate ratios were observed in the US study comparing FPNS with other INS for hypercorticism, sinusitis, abscess, and empyema, as well as a significantly decreased rate ratio for cataracts. The US claims database provided greater granularity on covariates and markers of severity to improve control of confounding for this study and time period, but neither database was able to assess the indication for prescription and the UK study could not address the use of INS without a prescription. CONCLUSIONS: The FPNS results were consistent with the risk profile for INS and did not raise any new safety signals at the time of study conduct, which is consistent with the current safety profile. We were not able to discern the extent of potential off-label use of FPNS or other INS. Differences in the available data and healthcare systems highlight important considerations for database selection in the feasibility phase to assess the precision and limitations prior to formal risk evaluation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40801-015-0057-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-02-19 /pmc/articles/PMC4819470/ /pubmed/27747804 http://dx.doi.org/10.1007/s40801-015-0057-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Davis, Kourtney J. Hinds, David Motsko, Stephen P. Goehring, Earl Jones, Judith K. Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title | Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title_full | Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title_fullStr | Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title_full_unstemmed | Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title_short | Intranasal Fluticasone Propionate Observational Cohort Safety Studies: Reviewing Evidence from Databases on Two Continents |
title_sort | intranasal fluticasone propionate observational cohort safety studies: reviewing evidence from databases on two continents |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819470/ https://www.ncbi.nlm.nih.gov/pubmed/27747804 http://dx.doi.org/10.1007/s40801-015-0057-y |
work_keys_str_mv | AT daviskourtneyj intranasalfluticasonepropionateobservationalcohortsafetystudiesreviewingevidencefromdatabasesontwocontinents AT hindsdavid intranasalfluticasonepropionateobservationalcohortsafetystudiesreviewingevidencefromdatabasesontwocontinents AT motskostephenp intranasalfluticasonepropionateobservationalcohortsafetystudiesreviewingevidencefromdatabasesontwocontinents AT goehringearl intranasalfluticasonepropionateobservationalcohortsafetystudiesreviewingevidencefromdatabasesontwocontinents AT jonesjudithk intranasalfluticasonepropionateobservationalcohortsafetystudiesreviewingevidencefromdatabasesontwocontinents |